These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29305921)

  • 41. Rat liver fibrosis regresses better with pegylated interferon alpha2b and ursodeoxycholic acid treatments than spontaneous recovery.
    Tasci I; Mas MR; Vural SA; Comert B; Alcigir G; Serdar M; Mas N; Isik AT; Ates Y
    Liver Int; 2006 Mar; 26(2):261-8. PubMed ID: 16448466
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative Pharmacokinetics, Tissue Distribution, Excretion of Recombinant LiverTargeting Interferon with IFN α2b Administered Intramuscular in Rats.
    Wang J; Lu X; Jin X; Zeng W; Zhu J
    Curr Pharm Biotechnol; 2015 Jul; ():. PubMed ID: 26212562
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Interferon alpha-2b modified with polyethylene glycol].
    Wu Y; Zhai Y; Lei J; Ma G; Su Z
    Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1658-63. PubMed ID: 19160853
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats.
    Ben Reguiga M; Bonhomme-Faivre L; Farinotti R
    J Pharm Pharmacol; 2007 Mar; 59(3):401-8. PubMed ID: 17331344
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lymphatic system of the pancreas.
    O'Morchoe CC
    Microsc Res Tech; 1997 Jun 1-15; 37(5-6):456-77. PubMed ID: 9220424
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of pegylated interferon α2b on metastasis of hepatocellular carcinoma.
    Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T
    J Surg Res; 2012 Jan; 172(1):95-101. PubMed ID: 20851413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pegylated IFNs for chronic hepatitis C: an update.
    Grace MJ; Cutler DL; Bordens RW
    Expert Opin Drug Deliv; 2005 Mar; 2(2):219-26. PubMed ID: 16296749
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of a non-covalent cell-penetrating peptide strategy to enhance the nasal delivery of interferon beta and its PEGylated form.
    Iwase Y; Kamei N; Khafagy el-S; Miyamoto M; Takeda-Morishita M
    Int J Pharm; 2016 Aug; 510(1):304-10. PubMed ID: 27343364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lymphatic transport and organ uptake of gelatin and hyaluronan injected into the rat mesentery.
    Ostgaard G; Hellevik T; Reed RK; Smedsrød B
    Acta Physiol Scand; 1995 Jan; 153(1):51-60. PubMed ID: 7625168
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection.
    Charman SA; Segrave AM; Edwards GA; Porter CJ
    J Pharm Sci; 2000 Feb; 89(2):168-77. PubMed ID: 10688746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.
    Han S; Quach T; Hu L; Wahab A; Charman WN; Stella VJ; Trevaskis NL; Simpson JS; Porter CJ
    J Control Release; 2014 Mar; 177():1-10. PubMed ID: 24398334
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting colloidal particulates to thoracic lymph nodes.
    Liu J; Wong HL; Moselhy J; Bowen B; Wu XY; Johnston MR
    Lung Cancer; 2006 Mar; 51(3):377-86. PubMed ID: 16413084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toxicology and carcinogenesis studies of 3,3',4,4'-tetrachloroazobenzene (TCAB) (CAS No. 14047-09-7) in Harlan Sprague-Dawley rats and B6C3F1 mice (gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2010 Nov; (558):1-206. PubMed ID: 21383777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.
    Vigani AG; Gonçales ES; Pavan MH; Genari F; Tozzo R; Lazarini MS; Fais V; Feltrin A; Gonçales NS; Gonçales FL
    Braz J Infect Dis; 2012; 16(3):232-6. PubMed ID: 22729189
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Physicochemical and biologic properties of interferons and their potential uses in drug delivery systems.
    Bocci V
    Crit Rev Ther Drug Carrier Syst; 1992; 9(2):91-133. PubMed ID: 1378776
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
    Reddy KR
    Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lymphatic Distribution of Etanercept Following Intravenous and Subcutaneous Delivery to Rats.
    Gao X; Voronin G; Generaux C; Rose A; Kozhich A; Dalglish G; Rosa R; Oh S; Kagan L
    Pharm Res; 2020 Jul; 37(8):155. PubMed ID: 32720159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G; Tolvaj G; Halász T; Stotz G
    Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat.
    Ionac M; Oelkers R; Brune K; Geisslinger G; Bordos D
    Rom J Intern Med; 1996; 34(3-4):239-51. PubMed ID: 9167225
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Examination of lymphatic transport of puerarin in unconscious lymph duct-cannulated rats after administration in microemulsion drug delivery systems.
    Wu H; Zhou A; Lu C; Wang L
    Eur J Pharm Sci; 2011 Mar; 42(4):348-53. PubMed ID: 21216284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.